Physician profile
Charles A Weber
NPI 1144213042
$518.15
in general payments reported to CMS, 2019-2025
10 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.03 · 2020: $51.56 · 2021: $12.27 · 2022: $40.91 · 2023: $99.70 · 2024: $140 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310 · Education: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.38 |
| Education | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $117.39 | 2024-2025 | |
| Abbvie INC. | $113.76 | 2021-2025 | Qulipta |
| Horizon Therapeutics Plc | $65.94 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $56.79 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $43.00 | 2024 | Lupkynis |
| Genentech USA, INC. | $35.95 | 2019 | |
| Genzyme Corporation | $31.47 | 2025 | |
| Amgen INC. | $28.90 | 2022-2025 | Otezla |
| Organon LLC | $12.90 | 2023 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.